ABNORMAL HAEMATOLOGICAL PARAMETERS IN EC 167 7 Table 2. Clinicopathological characteristics in relation to haemoglobin-, leukocytes- and thrombocytosis-level Normal haemoglobin (n=791) Anaemia (n=103) P Normal platelets (n=642) Thrombocytosis (n=79) P Normal leukocytes (n=553) Leucocytosis (n=114) P Patient characteristics Age 65.7 (27.2-91.0) 68.2 (33.8-93.8) 0.246 66.0 (31.2-93.8) 64.0 (27.2-90.7) 0.017* 66.0 (31.2-93.8) 65.0 (27.2-86.0) 0.386 Final tumour histology Tumour grade 1-2 560 (70.8) 60 (58.3) 0.009* 448 (69.8) 52 (65.8) 0.471 383 (69.3) 81 (71.1) 0.705 3 231 (29.2) 43 (41.7) 194 (30.2) 27 (34.2) 170 (30.7) 33 (28.9) Endometrioid 656 (82.9) 79 (76.7) 0.120 531 (82.7) 62 (78.5) 0.353 455 (81.7) 94 (82.5) 0.856 Non-endometrioid 135 (17.1) 24 (23.3) 111 (17.3) 17 (21.5) 101 (18.3) 20 (17.5) LVSI Yes 149 (18.8) 28 (27.2) 0.046* 121 (18.8) 23 (29.1) 0.031* 109 (19.7) 26 (22.8) 0.454 No 642 (81.2) 75 (72.8) 521 (81.2) 56 (70.9) 444 (80.3) 88 (77.2) ESGO/ESTRO/ESP risk groups Low risk 372 (47.0) 37 (35.9) 0.033* 309 (48.1) 31 (39.2) 0.135 270 (48.8) 53 (46.5) 0.650 Intermediate risk 146 (18.5) 12 (11.7) 0.088 105 (16.4) 7 (8.9) 0.083 77 (13.9) 17 (14.9) 0.782 High-intermediate risk 140 (17.7) 22 (21.4) 0.364 114 (17.8) 17 (21.5) 0.413 101 (18.3) 17 (14.9) 0.393 High risk 114 (14.4) 27 (26.2) 0.002* 97 (15.1) 19 (24.1) 0.041* 92 (16.6) 20 (17.5) 0.813 Advanced/metastatic 19 (2.4) 5 (4.9) 0.148 17 (2.6) 5 (6.3) 0.073 13 (2.4) 7 (6.2) 0.031* Adjuvant treatment None 499 (63.1) 51 (49.5) 0.009* 412 (64.2) 42 (53.2) 0.066 361 (65.2) 64 (56.1) 0.069 RT VBT 122 (15.4) 10 (9.7) 0.124 87 (13.6) 3 (3.8) 0.013* 58 (10.5) 15 (13.2) 0.406 EBRT +/- VBT 87 (11.0) 20 (19.4) 0.012* 75 (11.6) 14 (17.7) 0.124 69 (12.5) 17 (14.9) 0.480 CT+CRT 79 (10.0) 21 (20.4) 0.002* 65 (10.1) 19 (24.0) <0.001* 62 (11.3) 17 (15.0) 0.260 Other 4 (0.5) 1 (1.0) 0.459 3 (0.5) 1 (1.3) 0.372 3 (0.5) 1 (0.8) 0.528 Data is presented in numbers (%), median (range), * P<0.05 Abbreviations: number (n), Lymphovascular space invasion (LVSI), European Society of Gynaecological Oncology (ESGO), European SocieTy for Radiotherapy and Oncology (ESTRO), European Society of Pathology (ESP), Radiotherapy (RT), Vaginal brachytherapy (VBT), External beam radiation therapy (EBRT), Chemotherapy (CT), Chemoradiation (CRT)
RkJQdWJsaXNoZXIy MTk4NDMw